Pfizer's Strategic Oncology Evolution
Cashu Finance·5 min read

TL;DR
- Pfizer's oncology portfolio expansion could mitigate patent losses.
- Recent acquisitions and FDA approvals enhance treatment options.
- CEO's optimism signals a potential turnaround for investor sentiment.
Pfizer Inc. ( PFE) continues to redefine its strategic trajectory in the face of industry challenges, particularly focusing on its oncology portfolio as a vital countermeasure against the impending patent cliffs threatening its revenue streams. The company’s recent initiatives, including key acquisitions and regulatory approvals, underscore its commitment to not only sustenance but growth within the pharmaceutical landscape.
Pfizer has faced a series of significant hurdles in recent years, primarily driven by the finite nature of its lucrative COVID-19 vaccine franchise and the impending loss of patent protections for blockbuster drugs like Eliquis and Ibrance.
The Shadows of Patent Expirations
looming over the company pose a considerable risk, with up to one-third of its revenue jeopardized over the next few years due to these patent expirations. As highlighted previously, Pfizer’s proactive actions, particularly its strategic acquisitions, position it favorably to counteract these losses.
Shifting Focus Towards Oncology
Recognizing the urgent need to pivot, Pfizer has embarked on an ambitious strategic course, notably their acquisition of Seagen for $43 billion. This major investment aims to expand its oncology capabilities, a sector projected to grow substantially over the coming decade, with an estimated market size of $280 billion by 2035. This acquisition aligns with Pfizer's commitment to redirect significant internal resources toward the development of cancer therapies, estimated at 40% of its research and development budget.

